Brolucizumab (Beovu®). HTA ID: 20009

Assessment Status Rapid Review complete
HTA ID 20009
Drug Brolucizumab
Brand Beovu®
Indication Treatment of neovascular (wet) age-related macular degeneration.
Assessment Process
Rapid review commissioned 26/02/2020
Rapid review completed 07/04/2020
Rapid review outcome A full HTA is recommended to assess the clinical and cost effectiveness of brolucizumab compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.